APC and posterior cortical atrophy: Previous studies have identified several epigenetic-based biomarkers with great potential for detection of clinically relevant PCa [revised in [5]], including the ProCaM assay (which evaluates GSTP1, APC, and RARβ2 promoter methylation in urine samples), as a positive result correlates with increased likelihood of finding high-grade PCa in prostate biopsy [10].